- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02708407
PD-HF: A Trial of Peritoneal Dialysis in Patients With Severe Heart Failure and Chronic Kidney Disease (PD-HF)
PD-HF: A Multi-centre Randomised Controlled Trial of Intermittent Peritoneal Dialysis With Icodextrin-based Solutions on Patients With Severe Heart Failure and Stage 3-4 Chronic Kidney Disease
연구 개요
상세 설명
The trial is a multi-centre, prospective, randomised, unblended, controlled trial of intermittent PD with a single daily exchange of icodextrin plus best standard care versus best standard care for the treatment of severe HF and moderate CKD. A second exchange with glucose based solution may be given, should it be required in the investigator's/clinician's opinion. Investigators will randomise 130 participants for 32 weeks with randomisation stratified by participating centre. Participants will be recruited from specialist-led outpatient HF services in 6 NHS trusts and be managed by both cardiologists and nephrologists.
PD catheter insertion will occur according to the participating centre's institutional protocol. Treatment begins 1 week after catheter insertion and consists of a single nightly exchange.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Derbyshire
-
Derby, Derbyshire, 영국, DE22 3DT
- Derby Teaching Hospitals NHS Foundation Trust
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Severe heart failure (NYHA grade III or IV)
- Chronic kidney disease stage 3-4
- Fluid overload resistant to diuretics OR hospital admission for HF in last 6 months
- Left ventricular ejection fraction ≤40% in last 2 years (moderate/severe)
- Using optimal HF medication for ≥ 4 weeks including ACE-inhibitor (angiotensin-converting-enzyme inhibitor) OR angiotensin receptor blocker AND aldosterone antagonist AND beta-blocker unless intolerant and without dose change for ≥ 4 weeks
- Appropriately screened for revascularization and/or cardiac resynchronization therapy if clinically indicated.
Exclusion Criteria:
- Does not wish to participate
- Mental incapacity to consent
- CKD stage 5
- Normal renal excretory function
- Haemodynamically significant valvular disease amenable to surgery
- Cardiac or renal transplantation
- Considered by the investigator to unsuitable for PD due to previous abdominal surgeries, peritonitis, social circumstances or other reason
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Peritoneal Dialysis Group
These participants will continue to receive standard HF care and Peritoneal Dialysis with a single daily exchange of icodextrin.
|
One week after insertion of a PD catheter the intervention group will received a single nightly exchange, using dialysis fluid containing icodextrin; a variable proportion of participants may require a second exchange as directed by the consultant nephrologist as part of routine care.
The second exchange would use dialysis fluid containing glucose, not icodextrin.
Support and training will be given to each participant by the PD specialist team.
|
간섭 없음: Control Group
These participants will continue to receive standard HF care.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
The primary end-point is a change of 25 metres walked
기간: Baseline to week 28
|
6 Minute Walk Test
|
Baseline to week 28
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Change in KCCQ score
기간: Baseline to week 28
|
Kansas City Cardiomyopathy Questionnaire
|
Baseline to week 28
|
Change in SF36 score
기간: Baseline to week 28
|
Short Form 36 questionnaire
|
Baseline to week 28
|
Change in Derby Evaluation of Illness online visual analogue scale
기간: Baseline to week 28
|
Derby Evaluation of Illness online visual analogue scale
|
Baseline to week 28
|
Heart Failure related hospitalisations
기간: Baseline to week 28
|
Recording the number of hospitalisations relating to Heart Failure
|
Baseline to week 28
|
All cause hospitalisations
기간: Baseline to week 28
|
Recording the number of hospitalisations for all causes
|
Baseline to week 28
|
Heart failure related mortality
기간: Baseline to week 28
|
Recording the number of heart failure deaths
|
Baseline to week 28
|
All cause mortality
기간: Baseline to week 28
|
Recording the number of all cause deaths
|
Baseline to week 28
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Episodes of PD associated peritoneal infection
기간: Baseline to week 28
|
Recording the numbers of PD associated peritoneal infections
|
Baseline to week 28
|
Adverse events spontaneously reported during the study
기간: Baseline to week 28
|
Recording and reporting adverse events
|
Baseline to week 28
|
Is the Derby Evaluation of Illness online visual analogue scale more sensitive than pen and ink questionnaires
기간: Baseline to week 28
|
Comparison between the scores from pen and ink questionnaires and the online visual analogue scale
|
Baseline to week 28
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Maarten Taal, University of Nottingham
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
심부전에 대한 임상 시험
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan University of... 그리고 다른 협력자들아직 모집하지 않음심부전, 수축기 | 박출률이 감소된 심부전 | 심부전 New York Heart Association Class IV | 심부전 New York Heart Association Class III폴란드
-
Novartis Pharmaceuticals완전한핵심 연구의 12개월 치료 기간을 성공적으로 완료한 환자(de Novo Heart Recipients)는 EC-MPS 치료에 관심이 있었습니다.
-
University of WashingtonAmerican Heart Association완전한심부전,울혈 | 미토콘드리아 변경 | 심부전 New York Heart Association Class IV미국
Peritoneal Dialysis에 대한 임상 시험
-
University Medical Center GroningenSt Jansdal Hospital완전한